Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Imaging FDG Flare in Melanoma
- Status
- COMPLETED
- Phase
- N/A
Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL)
- Status
- UNKNOWN
- Phase
- PHASE2
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)
- Status
- COMPLETED
- Phase
- PHASE3
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia
- Status
- TERMINATED
- Phase
- PHASE2
Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
- Status
- TERMINATED
- Phase
- PHASE1